title: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.
abstract: In children with acute lymphoblastic leukemia (ALL), response to treatment is assessed by bone marrow aspiration. We investigated whether minimal residual disease (MRD) can be effectively monitored in peripheral blood. We used flow cytometric techniques capable of detecting 1 leukemic cell among 10 000 or more normal cells to compare MRD measurements in 718 pairs of bone marrow and peripheral blood samples collected from 226 children during treatment for newly diagnosed ALL. MRD was detected in marrow and blood in 72 pairs and in marrow but not in blood in 67 pairs; it was undetectable in the remaining 579 pairs. Remarkably, findings in marrow and blood were completely concordant in the 150 paired samples from patients with T-lineage ALL: for each of the 35 positive marrow samples, the corresponding blood sample was positive. In B-lineage ALL, however, only 37 of 104 positive marrow samples had a corresponding positive blood sample. Notably, peripheral blood MRD in these patients was associated with a very high risk for disease recurrence. The 4-year cumulative incidence of relapse in patients with B-lineage ALL was 80.0% +/- 24.9% for those who had peripheral blood MRD at the end of remission induction therapy but only 13.3% +/- 9.1% for those with MRD confined to the marrow (P =.007). These results indicate that peripheral blood may be used to monitor MRD in patients with T-lineage ALL and that peripheral blood MRD may provide strong prognostic information in patients with B-lineage ALL.
authors.affiliation: Departments of Hematology-Oncology, Biostatistics, and Pathology, St Jude Children's Research Hospital, and the University of Tennessee, Memphis TN 38105-2794, USA.
authors.forename: Elaine
authors.initials: E
authors.lastname: Coustan-Smith
authors.forename: Jose
authors.initials: J
authors.lastname: Sancho
authors.forename: Michael L
authors.initials: ML
authors.lastname: Hancock
authors.forename: Bassem I
authors.initials: BI
authors.lastname: Razzouk
authors.forename: Raul C
authors.initials: RC
authors.lastname: Ribeiro
authors.forename: Gaston K
authors.initials: GK
authors.lastname: Rivera
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Rubnitz
authors.forename: John T
authors.initials: JT
authors.lastname: Sandlund
authors.forename: Ching-Hon
authors.initials: CH
authors.lastname: Pui
authors.forename: Dario
authors.initials: D
authors.lastname: Campana
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology*; D002648:Child; D018572:Disease-Free Survival; D005434:Flow Cytometry; D006801:Humans; D018365:Neoplasm, Residual / Q000097:blood* / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors